 The purpose of this trial is to assess the safety and efficacy of MDT-2113 for the interventional treatment of de novo and non-stented restenotic lesions in the superficial femoral artery SFA and the proximal popliteal artery PPA as compared to treatment with standard percutaneous transluminal angioplasty PTA. 